Improving prophylactic growth factor (pGCSF) use in non-small cell lung cancer (NSCLC) patients (pts) receiving chemotherapy (CT) at the Cleveland Clinic Taussig Cancer Institute (TCI).

Authors

Lindsey Martin Goodman

Cleveland Clinic Foundation, Cleveland, OH

Lindsey Martin Goodman, Machelle Moeller, Carole Kathleen Dalby, Amy E. Guthrie, Marc A. Earl, Nathan A. Pennell, Marc A. Shapiro, Vamsidhar Velcheti, Patrick C. Ma, James Stevenson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Effect of improving guideline-based prophylactic growth factor (pGCSF) use with chemotherapy (CT) on the risk of febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients (pts): A Cleveland Clinic Taussig Cancer Institute (TCI) Quality Improvement (QI) Project.

First Author: Lindsey Martin Goodman

insert_chart_outlined

Poster

2021 ASCO Quality Care Symposium

bookmark_border

Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).

First Author: Jaime Shaw

insert_chart_outlined

Poster

2019 Breakthrough

bookmark_border

Clinical study of gefitinib maintenance therapy after concurrent radiotherapy and chemotherapy for locally advanced NSCLC with EGFR sensitive mutations.

First Author: Ying Xin

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study.

First Author: Milena Bruzzone